ReviewCurrent neuropharmacology2015
Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology.
Review in Current neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- [Performance-related substance use in everyday life and work].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Exploring Cognitive Enhancers: from neurotherapeutics to ethical and regulatory challenges: a mini review.Annals of medicine and surgery (2012) · 2025Review
- Bird's eye view of natural products for the development of new anti-HIV agents: Understanding from a therapeutic viewpoint.Animal models and experimental medicine · 2025Review
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Forensic approach in cases of anabolic-androgenic steroid abuse and cardiovascular mortality: insights from autopsy, histopathology, immunohistochemistry and toxicology.Frontiers in cardiovascular medicine · 2025Review
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.Journal of analytical toxicology · 2022Review
- Review
- Herbal drugs and natural bioactive products as potential therapeutics: A review on pro-cognitives and brain boosters perspectives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Review
- The effect of piracetam on behavioral reactions of adult rats and morphological changes in the brain after whole body fractionated gamma irradiation: an exploratory study.Radiation and environmental biophysics · 2021Article
- Non-medical Use of Prescription Stimulants Among College Students: Non-oral Routes of Administration, Risk Factors, Motivations, and Pathways.Frontiers in psychiatry · 2021Article
- Metabolic Syndrome Associated with Tobacco and Caffeine Products Use Among Refugee Adolescents: Risk of Dyslipidemia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Neuroprotective effects of magnesium L-threonate in a hypoxic zebrafish model.BMC neuroscience · 2020Article
- The Psychonauts' World of Cognitive Enhancers.Frontiers in psychiatry · 2020Article
- Pharmacological Human Enhancement: An Overview of the Looming Bioethical and Regulatory Challenges.Frontiers in psychiatry · 2020Review
- Probiotics and Psychobiotics: the Role of Microbial Neurochemicals.Probiotics and antimicrobial proteins · 2019Review
- Use of Methylphenidate Analogues as Cognitive Enhancers: The Prelude to Cosmetic Neurology and an Ethical Issue.Frontiers in psychiatry · 2019Article
- Anabolic Androgenic Steroids: Searching New Molecular Biomarkers.Frontiers in pharmacology · 2018Review
- Lipid peroxidation and apoptotic response in rat brain areas induced by long-term administration of nandrolone: the mutual crosstalk between ROS and NF-kB.Journal of cellular and molecular medicine · 2016Article
- From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.Current neuropharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive enhancement can be defined as the use of drugs and/or other means with the aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity and intelligence in the absence of any medical indication. Currently, it represents one of the most debated topics in the neuroscience community. Human beings always wanted to use substances to improve their cognitive functions, from the use of hallucinogens in ancient civilizations in an attempt to allow them to better communicate with their gods, to the widespread use of caffeine under various forms (energy drinks, tablets, etc.), to the more recent development of drugs such as stimulants and glutamate activators. In the last ten years, increasing attention has been given to the use of cognitive enhancers, but up to now there is still only a limited amount of information concerning the use, effect and functioning of cognitive enhancement in daily life on healthy subjects. The first aim of this paper was to review current trends in the misuse of smart drugs (also known as Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk in healthy individuals, especially teenagers and young adults. Moreover, the authors have explored the issue of cognitive enhancement compared to the use of Anabolic Androgenic Steroids (AAS) in sports. Finally, a brief overview of the ethical considerations surrounding human enhancement has been examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.